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Summary. We propose a flexible design for the identification of optimal dose combina-
tions in dual-agent dose-finding clinical trials. The design is called AAA, standing for three
adaptations: adaptive model selection, adaptive dose insertion, and adaptive cohort divi-
sion. The adaptations highlight the need and opportunity for innovation for dual-agent dose
finding, and are supported by the numerical results presented in the proposed simulation
studies. To our knowledge, this is the first design that allows for all three adaptations at
the same time. We find that AAA improves the statistical inference, enhances the chance
of finding the optimal dose combinations, and shortens the trial duration. A clinical trial is
being planned to apply the AAA design.
Keywords: Adaptive cohort division; Bayesian inference; Dose combination; Hierar-
chical models; Markov chain Monte Carlo simulation; Phase I/II clinical trial.
1. Introduction
Dual-agent dose-finding trials are becoming much more popular in oncology as more
and new drugs become available. The traditional two-agent dose-finding trials often aim
to capture the dose-toxicity relationship for the combinations and identify one or more
maximum tolerated dose combination (MTDC) of two agents. The MTDC is defined as
the dose combination at which the probability that a patient experiences dose limiting
toxicity (DLT) is less than a prespecified target rate pT , which is usually determined
by physicians or clinical teams. A large number of designs have been proposed to find
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the MTDC for trials with cytotoxic agents. For example, Yin and Yuan (2009) in-
troduced Bayesian dose-finding approaches using copula regression models. Braun and
Wang (2010) developed a novel hierarchical Bayesian design accounting for patients het-
erogeneity, and Hirakawa et al. (2013) developed a likelihood-based dose-finding method
using a shrinkage logistic model. Conaway et al. (2004) estimated the MTDC by de-
termining the complete and partial orders of the toxicity probabilities using nodal and
non-nodal parameters. Later, Wages et al. (2011) applied model selection to estimate
possible complete orderings associated with the partial order based on the continual
reassessment method (CRM). As a review, Hirakawa et al. (2015) compared these five
model-based dose-finding designs. They found that the performance of designs varied
depending on the dose matrix and the location and number of true MTDCs. More re-
cently, Mander and Sweeting (2015) published a curve-free method that relied on the
product of independent beta probabilities. Lin and Yin (2016) developed a Bayesian
optimal interval design for dual agents. Sun and Braun (2015) proposed a two-stage
adaptive algorithm based on modified biased coin design, and Wages (2016) extended
the CRM to identify an MTDC contour for dual agents.
A key assumption to all the works above is the monotonicity of the dose-toxicity
response and the dose-efficacy response, which is true in the case of cytotoxic agents
(Le Tourneau et al., 2009). As for many new cancer biological or immunological agents,
such as the chimeric antigen receptors T-cell (CAR-T) therapies, such monotonic re-
lationship may not be true, especially for dose-efficacy relationship (Li et al., 2016).
For example, the dose-efficacy curves may follow a non-monotonic pattern, and efficacy
may even decrease at higher dose levels (Hoff and Ellis, 2007). Therefore, traditional
dose-finding designs with a focus on finding the MTDC are not suitable for trials of
non-cytotoxic agents. In contrast to the various literature for dual cytotoxic agents dose
finding, there is a scarcity of designs for non-cytotoxic agents dose finding. Instead of
identifying the MTDC, one could consider the biologically optimal dose combination
(BODC) for biological agents, the definition of which takes into account both efficacy
and toxicity. Wages and Conaway (2014) provided a phase I/II adaptive design to find
a single dose combination with an acceptable level of toxicity that maximized efficacious
response. However, they assumed that the dose-toxicity and dose-efficacy relationships
are monotonic among doses of one agent when the dose of other agent is fixed. Cai et al.
(2014) proposed a novel dose-finding algorithm to encourage sufficient exploration of un-
tried dose combinations in the two-dimensional space. Guo and Li (2015) used isotonic
regression to estimate partially stochastically ordered marginal posterior distributions
of the efficacy and toxicity probabilities to estimate the BODC.
For dual-agent trials, due to the challenges in capturing the proper therapeutic range
for the dose levels of both agents, the BODC might locate outside the candidate dose
range or sandwiched by existing dose combinations. Therefore, a design capable of
extrapolating or interpolating a new dose combination when candidate dose combinations
are deemed suboptimal can drastically improve one’s chance to identify better dose
combinations. To this end, Hu et al. (2013) considered an adaptive dose insertion scheme
to allow new doses to be inserted during the course of a dose-finding trial. Later,
Chu et al. (2016) introduced an extended version. Both methods only consider toxicity
outcomes. Guo et al. (2015) proposed a toxicity- and efficacy- based dose insertion
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design with adaptive model selection (TEAMS) for single-agent trials, and illustrated
the importance of correct model specification for dose insertion. They showed that in
order to insert the right doses, the dose-efficacy relationship must be properly identified.
In this paper, we extend the idea of TEAMS to dual agents and propose the AAA
(triple A) design. The AAA design is named after three adaptive features. First, to
describe the appropriate dose-efficacy curve, we present an adaptive Bayesian model
selection procedure based on median posterior probability models (Barbieri and Berger,
2004) that allows the dose-efficacy model to vary between the monotone pattern and non-
monotone pattern. Second, with the correct models being selected, we propose adaptive
dose insertion allowing new dose combinations to be extrapolated or interpolated during
the course of the trial. Last, importantly and innovatively, we consider adaptive cohort
division (ACD) and allow multiple cohorts of patients to be enrolled simultaneously
during the course of the trial. We show that ACD accelerates trial conduct and shortens
trial duration.
We consider a conceived clinical study at The University of Chicago involving a MEK
inhibitor and a PIK3CA inhibitor, both with four doses at their regular monotherapy
dose, two lower doses and one higher dose. This Phase I dose finding study will enroll
late-stage caner patients with a primary endpoint aiming to improve efficacy rate from
5% to 30% with the optimal tolerated dose combination. We will use this study as the
basis for our numerical studies later.
The remainder of this article is organized as follows. In Sections 2 and 3, we describe
the probability model and the AAA design. In Section 4, using the phase I trial we
examine the operating characteristics of the AAA design through simulation studies. To
evaluate the time reduction by using ACD, we examine the duration of the trial in the
simulated trials. We conclude with a brief discussion in Section 5.
2. Methods
2.1. Dose-response models
Consider a trial combining J doses of agent A, denoted by xa,1 < · · · < xa,J , and K doses
of agent B, denoted by xb,1 < · · · < xb,K , for dose finding. Without loss of generality, we
assume J ≥ K and that the dosage values of the xa,j ’s and xb,k’s have been standardized
to have mean 0 and standard deviation 0.5. Let xjk = (xa,j , xb,k) denote the combination
of dose levels j and k, and let p(xjk) and q(xjk) denote probabilities of the toxicity event
and efficacy event for the dose combination (xa,j , xb,k), respectively, for j = 1, 2, . . . , J ,
and k = 1, 2, . . . ,K.
Assume that p(x) follows a linear logistic model and q(x) follows a quadratic logistic
model in order to incorporate a non-monotone pattern in the dose-efficacy model
logit{p(x)} = α0 + α1xa + α2xb, (1)
logit{q(x)} = β0 + β1xa + β2xb + β3x2a + β4x2b , (2)
where α1 > 0, α2 > 0, and x = (xa, xb) is the vector of the dose combination. Later
we briefly discuss adding an interaction term β5xaxb in the last section. Denote α =
(α0, α1, α2)
′ and β = (β0, β1, β2, β3, β4)′, the vector of regression parameters in the dose-
toxicity model (1) and dose-efficacy model (2), respectively. Here, we use a working
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model and assume that the binary outcomes of toxicity and efficacy are independent.
This working independence between efficacy and toxicity outcome in dose-finding designs
has been extensively discussed in the literature (Cai et al., 2014; Ivanova et al., 2009).
We also assume that toxicity is monotone with the dose as a conservative choice of model.
In other words, α1 > 0 and α2 > 0 in model (1).
2.2. Utility function and definition of BODC
Utility-based decision criteria have been adopted frequently in recent dose-finding trials
(Thall and Nguyen, 2012; Lee et al., 2015; Quintana et al., 2016; Li et al., 2016). In
this paper, we construct utility functions for dose safety and efficacy evaluation. Denote
UT (p(x), η0) and UE(q(x), η˜) the utility for safety and efficacy at dose combination
x = (xa, xb), respectively, and define
UT (p(x), η0) =
{
1− 1−η0pT p(x), p(x) ∈ (0, pT ],
0, p(x) ∈ (pT , 1),
(3)
UE(q(x), η˜) = η1 · exp{η2 · q(x)}+ η3, η2 > 0, (4)
where η˜ = (η1, η2, η3)
′. See Figure 1 for an illustration. Here, the utility for safety UT
in (3) is a truncated linear decreasing function with p(x); we assume that the toxicity
utility UT decreases with toxicity probability and drops to 0 if p(x) > pT , i.e., there
is no utility when toxicity probability p(x) is larger than pT . Usually pT is around 0.3
for oncology trials. The utility for efficacy UE in (4) follows an exponential function
with parameters η1, η2 and η3, where (η1 + η3) decides the utility value when there is
no efficacy and (η1, η2) decide how fast utility increases when efficacy probability q(x)
increases. Combining the utilities for toxicity and efficacy, we define the overall utility
score as
U(x,η) = UT (p(x), η0) · UE(q(x), η˜), (5)
where η = (η0, η1, η2, η3)
′.
Then the biologically optimal dose combination (BODC), xopt = (xa,opt, xb,opt), is
defined as the dose combination that maximizes the utility function, i.e.
xopt(θ) = argmax
x
U(x,θ).
To specify the unknown values (η0, η1, η2, η3), we follow a procedure suggested by
Thall and Cook (2004). We elicit with physicians two pairs of toxicity-efficacy trade-off,
(0, q∗1) and (pT , q∗2), that have the same utility value U∗, say U∗ = 0.3. For example,
q∗1 = 0.1, q∗2 = 0.3. This gives the two equations: UT (0, η0) · UE(q∗1, η˜) = U∗ and
UT (pT , η0) · UE(q∗2, η˜) = U∗. In addition, UT and UE must have the same scale (0, 1),
which implies that 1) UE(q(x) = 0, η˜) = η1 + η3 = 0; and 2) UE(q(x) = 1, η˜) =
η1 · exp(η2) + η3 = 1. Therefore, we have a set of four nonlinear equations and four
unknown parameters. The numerical solution of ηˆ can be easily solved numerically.
2.3. Adaptive model selection for the dose-efficacy model
Efficacy could be either monotone or non-monotone with dose combination, depending on
many factors such as the pharmacology and mechanism of action of the drug. Proposing
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adaptive model selection, we allow adaptation in the model choice throughout the trial.
Briefly, when the number of explored dose combinations or the sample size is small,
a simpler model, such as a linear logistic model, may fit the data better to avoid the
wrong estimation of dose-response curve due to the model mis-specification. As the trial
proceeds, more dose combinations are explored, more patient data are accumulated, and
more complex models such as a non-monotone quadratic logit model might be beneficial
to obtain better estimates (Guo et al., 2015).
Consider a model selection framework for the efficacy regression coefficients in (2) as
follows:
M1 : β3 = β4 = 0; M2 : β3 6= 0, β4 = 0; M3 : β3 = 0, β4 6= 0; M4 : β3 6= 0, β4 6= 0.
Similar to Guo et al. (2015), we adopt the inverse moment priors (iMOM) (Johnson and
Rossell, 2010) on β3 under M2 and M4, β4 under M3 and M4, in which cases either or
both of them are assumed to be non-zero. The iMOM prior has no probability mass at
the null point (βi = 0, i = 3, 4) and takes the form
pi(βi|Ml) = kτ
ν/2
Γ(ν/2k)
|βi|−(ν+1) exp
(
τk
β2ki
)
, (i, l) ∈ {(3, 2), (3, 4), (4, 3), (4, 4)}
for k, ν, τ > 0. The choice of iMOM prior is discussed in detail in Appendix A. The prior
when β3 and β4 equals zero is simply a point mass at zero, i.e.
pi(βi|Ml) = 1{βi = 0}, (i, l) ∈ {(3, 1), (3, 3), (4, 1), (4, 2)},
where 1{·} is the indicator function. With no evidence favoring any of the hypotheses
over the others a priori, we take P (M1) = P (M2) = P (M3) = P (M4) = 1/4.
In the model selection, we compute P (Ml|Data), the posterior probability of each
model and select the median probability model (MPM) to be the dose response model.
MPM is defined as the model consisting of those variables which have overall posterior
probability greater than or equal to 1/2 (Barbieri and Berger, 2004). Specifically, in this
paper, denote p3 and p4 the posterior inclusion probability for the quadratic terms x
2
a
and x2b , respectively, and define
p3 = P (M2|Data) + P (M4|Data), (6)
p4 = P (M3|Data) + P (M4|Data), (7)
which are also the overall posterior probability that β3 6= 0 and β4 6= 0, respectively.
The posterior probability of model Ml, P (Ml|Data) in (6) and (7), l = 2, 3, 4, is given
by
P (Ml|Data) = P (Data|Ml)P (Ml)∑4
l=1 P (Data|Ml)P (Ml)
,
where P (Data|Ml) is the marginal distribution of the data under the prior of model Ml,
given by
P (Data|Ml) =
∫
pi(α,βl|Ml)L(Data|α,βl,Ml)dαdβl.
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Here L(Data|α,βl,Ml) is the likelihood function under model Ml, l = 1, 2, 3, 4, β1 =
{β0, β1, β2, β3 = β4 = 0}, β2 = {β0, β1, β2, β3, β4 = 0}, β3 = {β0, β1, β2, β3 = 0, β4}
and β4 = {β0, β1, β2, β3, β4}. Since the integral does not have a closed form, numerical
integration such as Monte Carlo integration is applied. Specifically, we use the harmonic
mean of likelihood values here (Kass and Raftery, 1995). Let β
(1)
l ,β
(2)
l , . . . ,β
(B)
l be a
Markov chain Monte Carlo (MCMC) sample from the posterior distribution of βl under
model Ml; suppressing terms related to α it can be shown that∫
pi(βl|Ml)L(Data|βl,Ml)dβl ≈
{
1
B
B∑
b=1
L(Data|β(b)l ,Ml)−1
}−1
,
for l = 1, 2, 3, 4. Kass and Raftery (1995) showed that the harmonic mean approach
is more efficient than directly sampling from the prior, especially when the likelihood
function is highly concentrated in an area with low prior probabilities.
We perform model selection based on posterior inclusion probability, p3 and p4 (Table
1). For instance, If p3 ≥ 1/2 and p4 ≥ 1/2, the quadratic terms of both agents, x2a and
x2b , are included in the model (2), i.e. β3, β4 6= 0. Therefore, we select the model M4.
2.4. Adaptive dose combination insertion
The therapeutic window of two different drugs is often complex and difficult to delineate.
In a trial that prespecifies a set of dose combinations for investigation, a new dose
combination should be inserted when the BODC, xopt, is distant to all the existing dose
combinations in the trial. This is our second proposed adaptation. Mathematically,
we propose an activation rule for triggering the dose-insertion procedure. Let RC(xopt)
represent the C% (e.g., C = 90) posterior credible circular region of xopt, defined as
follows:
RC(xopt, r) = {(xa,opt, xb,opt) : Pr{(xa,opt − xa,0)2 + (xb,opt − xb,0)2 ≤ r | Data} = C%},
where (xa,0, xb,0) and r are the center and the radius of the circular region, respectively.
Define A as the indicator of dose insertion,
A =
{
1, if RC(xopt, r)
⋂{(xa,j , xb,k) : j = 1, . . . , J, k = 1, . . . ,K} = ∅,
0, if RC(xopt, r)
⋂{(xa,j , xb,k) : j = 1, . . . , J, k = 1, . . . ,K} 6= ∅, (8)
where ∅ denotes the empty set. When A = 1, the credible region does not cover any
existing dose combinations, and the dose-insertion procedure is activated. Otherwise,
the trial proceeds by treating the next cohort at one of the existing dose combinations.
2.5. Adaptive cohort division
Adaptive cohort division (ACD) is the third and an innovative adaptation. When two or
more doses are considered similarly desirable for the next cohort of patients based on the
collected data, the proposed AAA design allows patients to be enrolled simultaneously
in parallel cohorts.
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The main idea is as follows. When we encounter a toxic dose combination during the
trial, a de-escalation is needed that decreases the dose level of either drug. To increase
efficiency, we propose to de-escalate to two untried lower dose combinations with parallel
patient enrollment at both dose combinations. That is, we open two cohorts concurrently
in this case. Cohorts are collapsed if a new dose combination is inserted, in which case
the new single cohort will be enrolled at the inserted dose, or the multiple cohorts all
point to the same dose combination for future patients.
Because of the ACD procedure, multiple cohorts can be enrolled at the same time.
Some cohorts might finish enrollment and follow up faster than others. When a cohort
finishes follow up, the efficacy and toxicity response data of the patients in the cohort
are observed. At this point, a decision must be made as to the next dose combination for
future patients. However, at that moment there might be other cohorts still enrolling,
in which case some patients might still be followed without response data while others
might have completed follow up with outcomes. To fully use the existing information,
we include the patients with complete data in all cohorts in the inference and decision
making. In other words, we make a decision on the next dose combination based on the
response data from all completers from all cohorts. This achieves faster enrollment and
exploration of the new dose combinations, thereby shortening trial duration.
2.6. Likelihood and prior specification
Let yjk, zjk and njk be the numbers of toxicity responses, efficacy responses and total
patients treated at dose combination (xa,j , xb,k) when a cohort completes follow up during
the trial, for j = 1, 2, · · · , J , and k = 1, 2, · · · ,K. Note these numbers include all
completers in all cohorts. For the observed Data ≡ {(yjk, zjk, njk), j = 1, 2, · · · , J, k =
1, 2, · · · ,K}, the likelihood function under model Ml is the product of the binomial
densities, i.e.
L(Data|α,βl,Ml) ∝
J∏
j=1
K∏
k=1
p(xjk|α)yjk{1−p(xjk|α)}njk−yjkq(xjk|βl)zjk{1−q(xjk|βl)}njk−zjk
where l = 1, 2, 3, 4 index four different models. Denote piE(βl|Ml) and piT (α) the priors
for βl and α. Assuming the prior independence between βl and α, the joint conditional
posterior under ML is given by
pi(θl|Data,Ml) ∝ L(Data|α,βl,Ml)piE(βl|Ml)piT (α),
where θl = (α
′,β′l)
′.
For the prior specification of parameters in the efficacy model (2) other than β3
and β4, we use a weakly informative default prior for β0, β1 and β2, recommended by
Gelman et al. (2008). That is, β0 ∼ Cauchy(0, 10), and β1, β2 ∼ Cauchy(0, 2.5), where
Cauchy(c, d) denotes a Cauchy distribution with the center parameter c and the scale
parameter d. These weakly informative and appropriately regularized priors improves
the estimation stability and still ensures that the data are able to dominate the priors
(Gelman et al., 2008). For the iMOM priors for β3 and β4, we use the default values for
k and ν: k = ν = 1, recommended by Johnson and Rossell (2010). With respect to the
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choice of parameter τ , we provide a function of the dose level τ = f(x1, x2, · · · , xJ) to
set τ for different scenarios. See detail in Web Appendix A.
For the toxicity model (1), we also adopt the weakly informative default prior Cauchy(0, 10)
for intercept α0. We assign α1 and α2 independent gamma distributions with the shape
parameter of 0.5 and the rate parameter of 0.5. This gives mean 1 and variance 2.
3. Trial design
3.1. Overview
The proposed dose-finding design consists of two stages. Stage I is a run-in period, in
which we escalate the dose along the diagonal of the dose combination matrix in order
to explore the dose-combination space quickly and collect preliminary data for stage II.
This is similar to Cai et al. (2014). Stage I stops if we reach the highest dose combination
(xa,J , xb,K) or if we encounter a dose combination that violates the safety requirement,
i.e., Pr{p(xjk) > pT |Data} > ξ, where ξ is a prespecified safety cutoff probability and
often set to be close to 1, e.g. ξ = 0.95. If the dose matrix is not square (i.e., J > K),
after first escalating the dose along the diagonal to the (xa,K , xb,K), we escalate the dose
by holding the dose level of agent B at K and increasing the dose level of agent A from
(xa,K , xb,K) to (xa,K+1, xb,K) and so on. After stage I, the trials enters stage II, adaptive
dose finding.
In stage II, we apply the toxicity and efficacy probability models for inference, the
utility function for dose assessment, and the three adaptive procedures (model selection,
dose insertion and cohort division) in Section 2 for adaptive dose finding. A simple
flow chart in Figure 3 depicts the flow of stage II in the AAA design. Specifically, once
a cohort of patients completes follow up in the trial, we update the recorded outcome
data from existing doses and enrolled patients, generate MCMC posterior samples of the
parameters under M1, M2, M3 and M4 respectively, denoted by {θ(b)l , b = 1, 2, · · · , B},
l = 1, 2, 3, 4, and carry out the adaptive model selection based on the MPM using
the updated data. Suppose Ml∗ is selected, we obtain an MCMC posterior sample
of θl∗ under the selected Ml∗ . For each simulated values θ
(b)
l∗ from the b-th MCMC
iteration, b = 1, 2, · · · , R, we maximize the utility function U(x,θ(b)l∗ ) with respect to
dose combination x, to obtain a posterior sample of BODC, i.e.
xˆ
(b)
opt,l∗ = (xˆ
(b)
a,opt,l∗ , xˆ
(b)
b,opt,l∗) = argmax
x
U(x,θ
(b)
l∗ ), l
∗ ∈ {1, 2, 3, 4}, (9)
for which the posterior mean of BODC is estimated to be
xˆopt = (xˆa,opt, xˆb,opt) =
∑B
b=1 xˆ
(b)
opt,l∗
B
. (10)
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3.2. Deciding the next dose combination
We first compute the dose-insertion activator A using the posterior sample of BODC
{xˆ(b)opt,l∗ : b = 1, 2, · · · , B}, and let
Aˆ = 1
{
Pr
{
(xa,opt,l∗ − xˆa,opt)2 + (xb,opt,l∗ − xˆb,opt)2 ≤ rˆ
}
> C%
}
≈ 1
{
1
B
∑
b
1
{
x
(b)
a,opt,l∗ − xˆa,opt)2 + (x(b)b,opt,l∗ − xˆb,opt)2 ≤ rˆ
}
> C%
}
, (11)
where 1{·} is the indicator function and rˆ is the minimum Euclidean distance among
the distances between the center and the existing dose combinations, denoted by
rˆ = min
j,k
{√
(xa,j − xˆa,opt)2 + (xb,k − xˆb,opt)2
}
.
We can easily see that Aˆ in (11) is a posterior estimate of (8).
If dose insertion is needed, i.e., Aˆ = 1, we insert the new dose combination (xˆa,opt, xˆb,opt)
and two sets of new dose combinations
{(xa,1, xˆb,opt), · · · , (xa,J , xˆb,opt)} and {(xˆa,opt, xb,1), · · · , (xˆa,opt, xb,K)}
into the dose combination matrix, as shown in Figure 2, and assign the next cohort to
the new dose combination (xˆa,opt, xˆb,opt).
If dose insertion is not needed, i.e., Aˆ = 0, we assign the next cohort of patients
according to the utility of the existing dose combinations. Let N denote the prespecified
maximum sample size, N1 denote the number of patients in stage I, and N2 = N −N1
be the total number of patients available for stage II. Given the current dose combina-
tion xjk = (xa,j , xb,k), we define 1-degree admissible dose set, denoted by A1, as dose
combination xj′k′ , whose dose levels are different from xjk no more than 1 level and
satisfy the safety requirement, i.e., A1 = {xj′k′ : |j′ − j| ≤ 1, |k′ − k| ≤ 1, P r{p(xj′k′) >
pT |Data} ≤ ξ}, where ξ is close to 1. Then the next dose combination is decided based
on the following algorithm:
If (xa,j , xb,k) is considered safe, i.e., Pr{p(xjk) > pT |Data} ≤ ξ, where ξ is close to
1, assign patients as follows:
[a.] Based on the accumulated trial data, determine dose set A1.
[b.] Among the dose combinations in A1, compute the posterior mean utility for
each combination, i.e., U¯(xj′k′ ,θl∗) =
1
B
∑B
b=1 U(xj′k′ ,θ
(b)
l∗ ), xj′k′ ∈ A1 and identify the
dose combination xj∗k∗ = (xa,j∗ , xb,k∗) with the highest posterior mean utility under the
safety constrain (j∗ − j) + (k∗ − k) ≤ 1, i.e.,
xj∗k∗ = argmax
xj′k′
{U¯(xj′k′ ,θl∗)} subject to xj′k′ ∈ A1, and (j′ − j) + (k′ − k) ≤ 1 (12)
[c.] If dose combination xj∗k∗ has not been used to treat any patient thus far, or all
doses in A1 have been used to treat patients, we assign the next cohort of patients to
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xj∗k∗ . However, if xj∗k∗ has been used and there are some untried dose combinations in
A1, we assign the next cohort of patients to xj∗k∗ only if
Pˆ r{U(xj∗,k∗ ,θl∗) > U0 | Data} ≈ 1
B
B∑
b=1
1{U(xj∗k∗ ,θ(b)l∗ ) > U0} >
(
N2 − n2
N2
)ω
where U0 is the lowest acceptable utility value, n2 is the total number of patients that
have been treated in stage II and ω is a known tuning parameter controlling how stringent
the threshold is. Otherwise, exclude xj∗k∗ from A1 and return to step b.
If (xa,j , xb,k) is deemed toxic, i.e., Pr{p(xjk) > pT |Data} > ξ, de-escalate to the
untried 1-degree lower doses, xj−1,k = (xa,j−1, xb,k) or xj,k−1 = (xa,j , xb,k−1) or both.
That is, if both dose combinations exist and have not been used, two cohorts of patients
are recruited and assigned to (xa,j−1, xb,k) and (xa,j , xb,k−1), simultaneously. If only one
dose exists and has not been used, assign the next cohort of patients to this dose. If
both doses exist but both have been used, terminate this cohort and do not recommend
any dose for next cohort until there is a cohort newly completed.
As seen above, we adopt a concept of 1-degree admissible neighbor A1 in assigning
the next dose combinations when dose insertion is not needed. Cai et al. (2014) demon-
strate that this admissible neighbor and adaptive rule (step c) not only encourage the
exploration of untried dose combinations to avoid the problem of trapping in subop-
timal doses, but also restrict the dose escalation/de-escalation within the neighbors of
the current dose, avoiding dramatic dose changes and improving the reliability of the
dose-finding.
3.3. Dose-finding Algorithm
The AAA design is summarized in Box 1. Additional rules listed in Box 2 are for
ethics and stability concern. For brevity, we use “dose ”to denote a dose combination
hereinafter.
AAA Design 11
Box 1: The AAA design for phase I/II dose finding trials
The trial starts with the treatment of the first cohort of patients at the lowest dose (xa,1, xb,1). Suppose that
patients are being treated at dose xjk = (xa,j , xb,k). A dose is deemed toxic if Pr{p(xjk) > pT |Data} > ξ,
where ξ is close to 1; otherwise, the dose is safe. Let N1 and N2 denote the maximum sample size of stage
I and II, respectively. Let n2 be the number of patients currently enrolled in stage II.
Stage I Run in Period
I1 If dose (xa,j , xb,k) is safe, escalate diagonally and treat the next cohort at (xa,j+1, xb,k+1). If
j = k = K, escalate to (xa,j+1, xb,K).
I2 Stage I is complete when either dose (xa,j , xb,k) is deemed toxic or the highest dose combination
(xa,J , xb,K) is reached. Stage II starts.
Stage II Adaptive Dose Finding
II1 Once a cohort completes follow up, collect their efficacy and toxicity outcomes.
II2 Using the accumulated trial data on all the completers, generate MCMC posterior samples of
parameters under models M1, M2, M3 and M4, respectively, and carry out adaptive model
selection. Suppose model l∗ is selected, denote the MCMC posterior sample {θ(b)l∗ , b = 1, . . . , B}
under the selected dose-efficacy model Ml∗ , l
∗ ∈ {1, 2, 3, 4}.
II3 Obtain a posterior sample xopt under Ml∗ , i.e. {xˆ(b)opt,l∗ , b = 1, 2, · · · , B}, from (9). Then compute
the posterior mean BODC, xˆopt = (xˆa,opt, xˆb,opt), from (10), and the decision indicator Aˆ in (11).
(a) If Aˆ = 1, the new dose xˆopt is inserted in the trial and assigned to the next cohort. In addition,
two sets of doses, {(xa,1, xˆb,opt), · · · , (xa,J , xˆb,opt)} and {(xˆa,opt, xb,1), · · · , (xˆa,opt, xb,K)}, are
inserted as well. Then go to step II1 and wait for the completion of this cohort.
(b) If Aˆ = 0 and xjk is safe,
b1) identify A1 as the set of safe neighbors of xjk with degree 1.
b2) In A1, identify the dose xj∗k∗ that has the highest posterior mean utility under the safety
constraint (j∗ − j) + (k∗ − k) ≤ 1, from (12).
b3) If nj∗k∗ = 0 or nrs 6= 0, ∀ xr,s ∈ A1, treat the next cohort at dose xj∗k∗ . Otherwise,
if Pr{U(xj∗,k∗ ,θl∗ | Data) > U0} >
(
N2−n2
N2
)ω
, treat the next cohort at xj∗k∗ ;
otherwise, remove xj∗k∗ from A1 and go to step b2.
(c) If Aˆ = 0 and xjk is toxic, de-escalate to the untried 1-degree lower doses allowing cohort
division:
- If {j, k ≥ 2 and nj−1,k = nj,k−1 = 0}, simultaneously enroll two cohorts of patients at
both doses xj−1,k and xj,k−1;
- If {j, k ≥ 2 and nj−1,k = 0 but nj,k−1 > 0}, or {j ≥ 2, k = 1, and nj−1,k = 0}, assign the
next cohort to dose xj−1,k;
- If {j, k ≥ 2 and nj,k−1 = 0 but nj−1,k > 0}, or {k ≥ 2, j = 1, and nj,k−1 = 0}, assign the
next cohort to dose xj,k−1;
- Otherwise, terminate this cohort and do not recommend any dose.
(d) If no dose is recommended in (a)-(c), assign the next cohort to the dose xj˜k˜ which
has the highest posterior mean utility among all the existing safe doses, i.e., xj˜k˜ =
argmaxxj′k′{U¯(xj′k′ ,θl∗)}
II4 Repeat steps II1-II3 until the maximum sample size N = N1 +N2 is reached.
II5 Select the dose that has the highest mean utility among all tested safe doses, including the newly
inserted dose.
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Box 2: Practical rules
– Rule 1 [Dose extrapolation] The inserted new dose is not allowed to be more than
twice the highest dose or less than half of the lowest dose that has been used in the
trial.
– Rule 2 [Early Termination] If the lowest dose x11 = (xa,1, xb,1) is deemed toxic,
i.e., Pr{p(x11) > pT |Data} > ξ, where ξ is close to 1, and no new dose is inserted,
terminate the trial.
– Rule 3 [Dose Exclusion] If the dose xjk = (xa,j , xb,k) is deemed toxic, i.e.,
Pr{p(xjk) > pT |Data} > ξ, where ξ is close to 1, exclude doses {(xa,j′ , xb,k′) :
j′ = j, j + 1, . . . , J, k′ = k, k + 1, . . . ,K}, i.e. these doses will never be used in the
trial again.
– Rule 4 [No Skipping Dose] Restrict the escalation to 1 level increment, i.e. there is
no skipping in the escalation. Particularly, if the new dose intended for insertion is
higher than any unexplored dose, pause the insertion and go to step II3(b)-II3(d).
4. Simulation
4.1. Simulation setup
We consider the motivating trials combining two agents, a MEK inhibitor and a PIK3CA
inhibitor, each with 4 dose levels. The maximum sample size is 96 and cohort size is 3.
We investigate 10 different scenarios, and all scenarios assume a true linear or quadratic
logistic model for both agents in the dose-efficacy relationship, as shown in Figure 4.
For each scenario, 1,000 simulated trials are conducted. In the proposed design, we
set the MTD toxicity threshold pT = 0.3, the credible level threshold C% = 0.90,
the lowest acceptable utility value U0 = 0.1 and the tuning parameter ω = 2. The
probability threshold ξ = 0.95 for the practical rule and safe requirement. Regarding
the utility function, we assume that the two toxicity and efficacy rate pairs, (0, 0.45)
and (0.3, 0.85) have the same utility value 0.3. As a result, we obtain the estimated
ηˆ = (0.396, 0.385, 1.280,−0.385).
For MCMC computation, we adopt a standard random walk Metropolis-Hasting al-
gorithm. And for each chain, 10,000 MCMC samples are drawn with a burn-in size of
5,000 iterations. The MCMC mixed fast and well with no sign of convergence problems.
For comparison, we apply the design in Cai et al. (2014). For fairness, we slightly
modified this design by using the utility function rather than efficacy probability for
defining the dose in admissible dose set A. This typically improved the performance of
their design based on our experience. There is no dose insertion and model selection in
their algorithm. Therefore, we only compare the dose allocation and dose selection. To
demonstrate the benefit of adaptive cohort division, we turn off the ACD procedure in
AAA and apply a single cohort algorithm, in which we randomly select one dose in step
IIc if two doses are available for ACD. See Web Appendix B for details of the simulation
scheme for patients enrollment and follow-up.
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4.2. Operating characteristics
The operating characteristics of the proposed algorithm for Scenarios 1-6 are summarized
in Table 2 with seven sections per scenario. Section 1 gives a brief description of the
true dose response and the need for insertion. Sections 2 and 3 provide the mean
(standard deviation) of the posterior means across the 1,000 simulated trials for the
regression parameters in the dose-toxicity and dose-efficacy models, respectively. Section
4 summarizes the model selection frequencies. Section 5 lists the prespecified dose levels,
and the true toxicity and efficacy probabilities of all the doses. Section 6 presents the
detailed operating characteristics of the AAA design in terms of patient allocation and
dose selection. Lastly, Section 7 presents the results of the modified algorithm from Cai
et al. (2014). For brevity, we present simulation results for Scenarios 7-10 in Web Table
2.
In Scenario 1, the efficacy rates firstly increase and decrease later with both agents.
The true BODC xopt = (0.441, 0.476) is bracketed by doses (0.3, 0.35), (0.3, 0.65),
(0.6, 0.35) and (0.6, 0.65). Therefore, new dose should be inserted (Figure 4). From
Table 2, we see that the AAA design inserts new doses with mean (0.430, 0.448) in
59.3% of the simulated trials. The utility of the mean inserted dose combination under
the true model is 0.465, which is higher than that of all prespecified dose combinations.
Among all the patients, 25.9% are treated at the inserted new dose combinations. At the
end of 55.9% of the simulated trials, an inserted dose is claimed to be the BODC. The
mean selected BODC at the end of the trial is (0.456, 0.464), close to the true BODC.
Also, 90.5% of the trials correctly choose the quadratic logistic regression for both agents
for dose-efficacy curve at the end, and the posterior sample means of β are close to the
true values. Section 7 shows the selection percentages and patient allocation based on
Cai et al. (2014). The results are reasonable as most patients are allocated to the four
doses that surround the true BODC. However, since their design dose not allow dose
insertion, it cannot correctly identify the true BODC.
Scenario 2 has a similar pattern of dose-toxicity and dose-efficacy curves with Scenario
1. From Figure 4, there is no need for insertion. The AAA design only inserts new doses
in 15.5% of trials. The mean selected dose combination is (0.454, 0.466), close to the
true BODC (0.442, 0.477).
Scenario 3 reflects a setting where only a few doses are tolerable while others are
overly toxic (Figure 4). Because the utility of the existing doses x31 = (0.55, 0.2) and
x22 = (0.25, 0.5) are 0.240 and 0.217, respectively, which are not much different from the
utility of true BODC (0.41, 0.332), 0.297, only 29.6% of the trials insert new doses. Note
that in this scenario, AAA selects the true quadratic logistic model for the dose-efficacy
73% of the times, a smaller percentage than Scenarios 1 and 2. This is because only a
few patients (22.7% in total) are assigned to the doses at the upper right corner of the
dose matrix (shown in Figure 4) due to their high toxicity. Therefore, there is insufficient
amount of information for better model selection in this scenario.
Scenario 4 is a situation when all combinations are higher than MTD, and hence
8.6% of the trials are terminated at an early stage according to Practical Rule 2. Among
completed trials, the proportion of selecting the true quadratic model for efficacy is
67.8%. New dose combinations with a mean (0.354, 0.354) are inserted among 92.5% of
the completed trials, and 96.7% end with selecting new dose combinations as BODC.
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The mean selected dose combination is (0.242, 0.245), which is lower than the MTD and
close to the true BODC (0.304, 0.262). This scenario demonstrates the important safety
feature of the proposed design. Also, AAA not only stops the trial early due to toxicity,
it performs desirable dose insertion below all the prespecified doses and identifies the
correct BODC.
Unlike the previous four scenarios, Scenario 5 presents a situation where the pre-
specified dose matrix only covers the bottom-left corner of the quadratic dose-efficacy
curve. Thus, the efficacy grows with both agents and the true BODC (0.474, 0.472)
locates at the upper-right corner beyond the dose matrix. The insertion rate is 11.1%
and the mean selected BODC is (0.358, 0.345), which is poorly estimated. And all four
dose-efficacy models are selected at similar rates. There are two reasons. First, because
the prespecified doses do not cover a wide range of dose response surface, data on these
doses could not provide a good estimate of the entire curve. Second, with a relatively
small sample size N = 96, the simulated trials often run out of patients before the BODC
combination is reached. If a large N is allowed, the dose matrix could be extrapolated
well and the dose insertion algorithm would perform better (results not shown).
Scenario 6 assumes that the true dose-efficacy is a linear logistic model. About 32.2%
of the simulated trials insert new doses, which is as expected, and the linear model is
selected at a relatively high rate, 70.3%. A total of 28.7% of trials select the new doses
as the BODC with the mean (1.002, 0.341).
In Scenarios 7-10 (see Web Table 2), the dose-efficacy curves increase first and fall
later with one agent, but are monotone with the other agent. In addition, the true
BODC are all located outside the prespecified dose matrix at the right-side, top-side,
left-side and bottom-side regions, respectively. In all four scenarios, insertion is needed,
and the average insertion rates are 44.2%, 29.7%, 88.2% and 79.9%, respectively. The
mean selected doses are close to the true BODCs in all four scenarios.
Comparing to the results of Cai et al. (2014) in Section 7 of all scenarios, we can
see that the doses close to the true BODC are assigned more patients and selected
more frequently. This shows that their design performs well in general. However, when
encountering situations where dose insertion is needed, their design is unable to select
the true BODC due to the lack of dose insertion.
4.3. Time duration
Table 3 demonstrates the benefit of ACD in shortening trial duration. In particular, step
IIc in Box 1 is expected to speed up the trial process and reduce the time duration. It can
be seen from Table 3 that about 100 days or more can be saved across most scenarios with
the ACD procedure. The trial is never longer with ACD than without ACD. Scenarios
with more toxic doses result in more reduction of trial time. For example, for Scenario
3, the trial duration is reduced by about 400 days. However, if all doses are overly
toxic, the reduction of time duration is negligible, since cohort division is not allowed
for inserted doses. The performance of multiple cohorts and single cohorts are almost
the same in terms of the mean selected BODC, patients allocation, and the percentage
of being selected as the BODC.
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4.4. Sensitivity to sample size
Lastly, to evaluate the effect of sample size, we apply the algorithm with a smaller
sample size of 66 on Scenarios 1, 4 and 5. Results are summarized in Web Table 3.
We find the that the reduction of sample size has larger influence on Scenario 1 than
Scenarios 4 and 5. Specifically, for Scenario 1, the insertion rate is reduced to 42% (from
55.9%) and the proportion of selecting the correct quadratic model is declined to 87.5%
(from 90.5%), although the mean inserted dose combination (0.44, 0.455), and the mean
selected BODC (0.460, 0.466), are still close to the truth. Overall, the AAA perform
reasonably well with a significant reduction of sample size.
5. Discussion
We propose a new Bayesian adaptive dose insertion design for dual-agents phase I/II
oncology trials. The dose-insertion procedure based on both efficacy and toxicity enables
us to locate more desirable dose combinations. Bayesian model selection during the trial
allows the dose-efficacy relationship to be adapted between linear and quadratic logistic
models. The model selection has been shown be important (Guo et al., 2015) in dose
insertion and maintaining a high efficiency of the dose-finding trial. The adaptive cohort
division speeds up the trial process and shortens the time duration in most scenarios.
Simulation results show that the proposed design has superior operating characteristics.
The AAA design is a utility-based method. Clearly, the performance heavily de-
pends on the definition of utility. Although we choose utility as a multiplication of a
linear truncated function (safety utility) and an exponential function (efficacy) in this
paper, one can use other reasonable alternative utilities. Choosing an appropriate utility
function has to be done for individual trials and through discussion between clinicians
and statisticians. For different diseases and drugs, different trade-off between efficacy
and toxicity might be allowed. Nevertheless, changes on the utility function is a sep-
arate topic and does not affect the overall statistical design illustrated in Boxes 1 and
2. In other words, the algorithm presented therein is expected to find the optimal dose
combination with high likelihood based on the defined utility, however it is defined.
In our models, we do not include an interaction effect β5xaxb for the two agents for a
couple of reasons. First, our current clinical trial cannot afford to recruit a large number
patients, say a few hundreds, which is typically needed for estimating interaction terms
in a regression model reliably. Second, it has been demonstrated that for the purpose
of dose finding, a local fit with a working model of the response surface does not affect
much the efficiency of dose finding. That is, even when models are mis-specified (by not
including a true interaction term), the dose-finding decisions are not affected severely and
still lead to reasonable performance. This has been shown in Cai et al. (2014) and Wang
and Ivanova (2005) in the context of drug combination trials. To see this, we simulated
two scenarios consisting of the interaction term β5xaxb (Web Figure 2) and summarize
results in Web Table 4. We can see that the AAA design performs well in finding the
optimal dose combination and allocating patients to desirable dose combinations. The
inference on the the parameter of the interactive term β5 is biased. Typically, accurate
estimation of β5 requires a large sample size and well-placed dose combinations across
the dose-response surface. In our current example, we only have 4×4 dose levels for two
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agents, which leads to the difficulty in capturing the rotation of the efficacy curve, i.e.,
β5. We found that when we increased to a combination of 6 × 6 and 7 × 7 dose levels,
the interaction can be well estimated (results are not shown).
Supplementary Materials
Appendices, Tables, and Figures, referenced in Sections 2.3, 2.6, 4.1, 4.2 and 5, are
available with this paper at the online website.
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Fig. 1: Utility functions: From left to right are utility for safety (truncated at pT and
sharply decreases to 0), utility for efficacy and the overall utility contours.
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Fig. 2: The procedure of dose insertion. Black dots: prespecified dose combinations, red dots:
inserted dose combinations.
Fig. 3: A simple flow chart for stage II in the AAA design.
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Fig. 4: Ten scenarios in the simulation study. Black dots represent the prespecified dose
combinations. Red dots marks the true BODC. Blue contour: dose-utility contour. Black line:
dose combinations with toxicity probability pT . Any dose combinations beyond the pT line with
higher toxicity probability are of 0 utility.
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Table 1: Median probability model selection rules.
p3 p4 β3 β4 The Selected Dose-Efficacy Model
< 1/2 < 1/2 = 0 = 0 linear logistic model, M1
≥ 1/2 < 1/2 6= 0 = 0 Quadratic for agent A, M2
< 1/2 ≥ 1/2 = 0 6= 0 Quadratic for agent B, M3
≥ 1/2 ≥ 1/2 6= 0 6= 0 Quadratic for both agents A and B, M4
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Table 2: Simulation results for scenarios 1-6. For each scenario, 1,000 trials are con-
ducted on computer and the operating characteristics are summarized in seven sections.
Section 1 gives a brief description of the true dose response and the need for insertion
or not. Section 2 and 3 provide the average (standard deviation) of the posterior means
across 1,000 simulated trials for the regression parameters. Section 4 summarized the
model selection. Section 5 presents the true toxicity and efficacy probability at each
dose combination and Section 6 presents the detailed operating characteristics in terms
of patient allocation and dose selection. Section 7 demonstrates the results of the design
in Cai et al. (2014).
Scenario 1 % early stop: 0
1. Quadratic; Efficacy peaks in the left side of MTD; Insertion is needed.
2. Toxicity Parameter Estimation, True (α0, α1, α2) = (−1.58, 1.4, 1.06)
αˆ0 αˆ1 αˆ2
-1.546(0.315) 1.161(0.874) 1.041(0.823)
3. Efficacy Parameter Estimation,True (β0, β1, β2, β3, β4) = (1.45, 0.7, 0.59,−9.8,−7.29)
βˆ0 βˆ1 βˆ2 βˆ3 βˆ4
Linear NaN(NaN) NaN(NaN) NaN(NaN) . .
Quadratic of agent A 1.475(0.549) 0.464(1.661) 0.917(1.278) -22.318(8.56) .
Quadratic of agent B 1.195(0.439) 1.459(1.368) -0.256(1.589) . -23.177(8.323)
Quadratic of both agents 1.535(0.523) 0.527(1.56) 0.437(1.544) -13.758(6.928) -11.861(6.021)
4. Model Selection percentages
Linear Quadratic of agent A Quadratic of agent B Quadratic of both agents
0% 5.8% 3.7% 90.5%
5. True Toxicity and Efficacy Probability: Tox/Eff
Dose Level (A\B) 0.05 0.35 0.65 1
0.1 0.05/0.01 0.07/0.1 0.1/0.14 0.16/0.02
0.3 0.07/0.12 0.11/0.56 0.15/0.64 0.21/0.17
0.6 0.13/0.19 0.18/0.7 0.24/0.76 0.33/0.27
0.9 0.21/0.01 0.28/0.1 0.37/0.14 0.48/0.02
6. Dose Allocation and Selection Percentages %pts/%sel
BODC=(0.441,0.476), BMS:%ins=59.3%
Dose inserted: 0.43(0.111), 0.448(0.142); Dose selected: 0.456(0.109), 0.464(0.118)
Dose Level(A\B) 0.05 0.35 0.65 1 Dose inserted Dose selected
0.1 0.031/0 0.011/0.003 0.009/0.001 0.001/0 0.257/0.559 0.43/
0.3 0.01/0.001 0.162/0.086 0.115/0.098 0.006/0.001
0.6 0.017/0.01 0.189/0.184 0.09/0.054 0.02/0.002
0.9 0.001/0 0.004/0.001 0.019/0 0.058/0
7. Dose Allocation and Selection Percentages for Cai’s Algorithm (% early stop: 0): %pts/%sel
Dose Level(A\B) 0.05 0.35 0.65 1
0.1 0.031/0 0.008/0 0.009/0.004 0.001/0
0.3 0.009/0 0.219/0.185 0.225/0.271 0.004/0.001
0.6 0.013/0.002 0.299/0.399 0.116/0.136 0.016/0.002
0.9 0.001/0 0.002/0 0.016/0 0.031/0
Scenario 2 % early stop: 0
1. Quadratic; Efficacy peaks in the left side of MTD; Insertion is not needed
2. Toxicity Parameter Estimation, True (α0, α1, α2) = (−1.38, 1.38, 1.01)
αˆ0 αˆ1 αˆ2
-1.392(0.285) 1.13(0.913) 1.031(0.839)
3. Efficacy Parameter Estimation,True (β0, β1, β2, β3, β4) = (1.44,−1.03,−0.5,−9.52,−6.64)
βˆ0 βˆ1 βˆ2 βˆ3 βˆ4
Linear -0.952(0.53) 0.994(1.335) -0.432(0.896) . .
Quadratic of agent A 1.794(0.57) -0.88(2.51) 1.359(1.516) -34.834(13.359) .
Quadratic of agent B 2.413(0.674) 1.46(1.583) -0.688(2.026) . -40.72(14.957)
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Table 2 (continued)
Quadratic of both agents 1.776(0.509) -0.332(1.928) -0.275(1.686) -15.634(8.089) -11.464(5.703)
4. Model Selection percentages
Linear Quadratic of agent A Quadratic of agent B Quadratic of both agents
0.1% 7.4% 3.2% 89.3%
5. True Toxicity and Efficacy Probability: Tox/Eff
Dose Level (A\B) 0.1 0.45 0.75 1
0.1 0.05/0.02 0.08/0.14 0.12/0.1 0.15/0.02
0.45 0.1/0.32 0.15/0.79 0.21/0.72 0.27/0.3
0.7 0.16/0.18 0.23/0.64 0.3/0.55 0.38/0.17
0.9 0.22/0.02 0.31/0.14 0.39/0.1 0.47/0.02
6. Dose Allocation and Selection Percentages %pts/%sel
BODC=(0.442,0.477), BMS:%ins=15.6%
Dose inserted: 0.533(0.146), 0.575(0.142); Dose selected: 0.454(0.051), 0.466(0.093)
Dose Level(A\B) 0.1 0.45 0.75 1 Dose inserted Dose selected
0.1 0.031/0.001 0.022/0.006 0.003/0.002 0.001/0 0.042/0.063 0.611/
0.45 0.046/0.021 0.633/0.835 0.051/0.054 0.004/0
0.7 0.003/0 0.032/0.018 0.032/0 0.019/0
0.9 0/0 0.003/0 0.021/0 0.057/0
7. Dose Allocation and Selection Percentages for Cai’s Algorithm (% early stop: 0): %pts/%sel
Dose Level(A\B) 0.1 0.45 0.75 1
0.1 0.032/0.001 0.017/0.002 0.005/0.001 0.002/0
0.45 0.042/0.023 0.706/0.91 0.053/0.05 0.003/0
0.7 0.007/0 0.034/0.012 0.032/0.001 0.015/0
0.9 0.002/0 0.003/0 0.017/0 0.03/0
Scenario 3 % early stop: 0.001
1. Quadratic; Efficacy peaks in the right side of MTD; Only a few dose combos are tolerable; Insertion is needed.
2. Toxicity Parameter Estimation, True (α0, α1, α2) = (−0.25, 2.22, 2.05)
αˆ0 αˆ1 αˆ2
-0.208(0.346) 1.994(0.956) 1.792(0.794)
3. Efficacy Parameter Estimation,True (β0, β1, β2, β3, β4) = (1.69, 2.87, 0.14,−8.24,−3.75)
βˆ0 βˆ1 βˆ2 βˆ3 βˆ4
Linear 1.025(0.797) 6.108(2.633) 0.137(0.842) . .
Quadratic of agent A 1.126(0.538) 2.209(1.189) 1.122(0.856) -9.821(4.077) .
Quadratic of agent B 1.394(0.635) 4.565(1.637) -0.177(1.244) . -8.127(3.87)
Quadratic of both agents 1.891(0.62) 2.821(1.347) 0.212(0.966) -9.364(3.768) -5.297(2.104)
4. Model Selection percentages
Linear Quadratic of agent A Quadratic of agent B Quadratic of both agents
0.7% 24% 2.2% 73%
5. True Toxicity and Efficacy Probability: Tox/Eff
Dose Level (A\B) 0.2 0.5 0.75 1
0.05 0.07/0.03 0.15/0.1 0.27/0.1 0.44/0.04
0.25 0.11/0.27 0.24/0.58 0.4/0.58 0.59/0.34
0.55 0.24/0.62 0.44/0.86 0.62/0.86 0.78/0.69
0.9 0.48/0.24 0.69/0.54 0.82/0.54 0.91/0.3
6. Dose Allocation and Selection Percentages %pts/%sel
BODC=(0.41,0.332), BMS:%ins=29.6%
Dose inserted: 0.323(0.184), 0.286(0.148); Dose selected: 0.38(0.145), 0.336(0.151)
Dose Level(A\B) 0.2 0.5 0.75 1 Dose inserted Dose selected
0.05 0.032/0.005 0.034/0.01 0.025/0.002 0.011/0 0.075/0.189 0.408/
0.25 0.115/0.085 0.27/0.356 0.034/0.011 0.018/0.001
0.55 0.222/0.323 0.029/0.016 0.031/0 0.023/0
0.9 0.013/0.002 0.016/0 0.023/0 0.029/0
7. Dose Allocation and Selection Percentages for Cai’s Algorithm (% early stop: 0): %pts/%sel
Dose Level(A\B) 0.2 0.5 0.75 1
0.05 0.032/0.008 0.034/0.005 0.023/0.008 0.012/0
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Table 2 (continued)
0.25 0.117/0.079 0.285/0.367 0.037/0.023 0.009/0
0.55 0.32/0.499 0.033/0.01 0.031/0 0.018/0
0.9 0.013/0.001 0.007/0 0.009/0 0.023/0
Scenario 4 % early stop: 0.086
1. Quadratic; Efficacy peaks in the right side of MTD; All dose are overly toxic; Insertion is needed.
2. Toxicity Parameter Estimation, True (α0, α1, α2) = (0.51, 1.03, 0.67)
αˆ0 αˆ1 αˆ2
0.639(0.475) 1.039(0.592) 0.701(0.488)
3. Efficacy Parameter Estimation,True (β0, β1, β2, β3, β4) = (0.69,−3.2,−1.76,−4.8,−2.93)
βˆ0 βˆ1 βˆ2 βˆ3 βˆ4
Linear 1.209(0.825) 1.251(1.059) 0.453(0.911) . .
Quadratic of agent A 0.487(0.622) -3.273(1.669) 0.286(0.786) -5.286(1.899) .
Quadratic of agent B 0.857(0.699) 0.997(0.911) -2.232(1.488) . -3.727(1.782)
Quadratic of both agents 0.724(0.654) -2.92(1.58) -1.58(1.289) -4.749(1.756) -2.704(1.436)
4. Model Selection percentages
Linear Quadratic of agent A Quadratic of agent B Quadratic of both agents
1.5% 18.3% 6.8% 68.7%
5. True Toxicity and Efficacy Probability: Tox/Eff
Dose Level (A\B) 0.4 0.6 0.8 1
0.4 0.38/0.72 0.45/0.76 0.51/0.62 0.57/0.25
0.6 0.48/0.76 0.55/0.8 0.61/0.66 0.67/0.29
0.8 0.58/0.48 0.64/0.53 0.7/0.36 0.75/0.11
1 0.67/0.06 0.73/0.07 0.78/0.04 0.82/0.01
6. Dose Allocation and Selection Percentages %pts/%sel
BODC=(0.304,0.262), BMS:%ins=92.5%
Dose inserted: 0.354(0.219), 0.354(0.231); Dose selected: 0.242(0.073), 0.245(0.09)
Dose Level(A\B) 0.4 0.6 0.8 1 Dose inserted Dose selected
0.4 0.081/0.033 0.025/0 0.018/0 0.008/0 0.678/0.967 0.208/
0.6 0.023/0 0.032/0 0.015/0 0.005/0
0.8 0.014/0 0.015/0 0.026/0 0.013/0
1 0.006/0 0.004/0 0.013/0 0.024/0
7. Dose Allocation and Selection Percentages for Cai’s Algorithm (% early stop: 0.603): %pts/%sel
Dose Level(A\B) 0.4 0.6 0.8 1
0.4 0.568/1 0.066/0 0.033/0 0.018/0
0.6 0.064/0 0.04/0 0.03/0 0.009/0
0.8 0.034/0 0.028/0 0.034/0 0.016/0
1 0.018/0 0.007/0 0.011/0 0.023/0
Scenario 5 % early stop: 0
1. Quadratic; All dose are safe; The dose range only covers the bottom-left corner of the efficacy-dose curve. Insertion is needed.
2. Toxicity Parameter Estimation, True (α0, α1, α2) = (−2.8, 0.77, 0.52)
αˆ0 αˆ1 αˆ2
-3.115(0.808) 0.924(0.976) 0.869(0.932)
3. Efficacy Parameter Estimation,True (β0, β1, β2, β3, β4) = (−2.86, 3.56, 2.22,−1.2,−0.73)
βˆ0 βˆ1 βˆ2 βˆ3 βˆ4
Linear -3.671(1.283) 3.062(1.935) 2.93(1.762) . .
Quadratic of agent A -4.262(1.622) 3.814(2.555) 3.031(1.847) 0.318(2.519) .
Quadratic of agent B -4.078(1.506) 3.599(2.145) 3.006(2.131) . -0.05(2.547)
Quadratic of both agents -4.597(1.578) 4.238(2.504) 3.108(2.04) 0.372(2.612) -0.363(2.384)
4. Model Selection percentages
Linear Quadratic of agent A Quadratic of agent B Quadratic of both agents
25.4% 23.9% 23.2% 27.5%
5. True Toxicity and Efficacy Probability: Tox/Eff
Dose Level (A\B) 0.05 0.15 0.25 0.35
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0.05 0.03/0 0.03/0 0.04/0.01 0.05/0.01
0.15 0.04/0.01 0.05/0.02 0.05/0.04 0.07/0.07
0.25 0.05/0.02 0.06/0.06 0.07/0.14 0.09/0.24
0.35 0.07/0.06 0.08/0.16 0.1/0.31 0.11/0.46
6. Dose Allocation and Selection Percentages %pts/%sel
BODC=(0.474,0.472), BMS:%ins=11.1%
Dose inserted: 0.443(0.205), 0.243(0.166); Dose selected: 0.358(0.053), 0.345(0.041)
Dose Level(A\B) 0.05 0.15 0.25 0.35 Dose inserted Dose selected
0.05 0.031/0 0.007/0 0.008/0 0.016/0.001 0.025/0.051 0.625/
0.15 0.007/0 0.031/0 0.016/0 0.021/0.002
0.25 0.008/0 0.016/0 0.033/0.001 0.045/0.009
0.35 0.022/0 0.028/0.002 0.068/0.029 0.618/0.905
7. Dose Allocation and Selection Percentages for Cai’s Algorithm (% early stop: 0): %pts/%sel
Dose Level(A\B) 0.05 0.15 0.25 0.35
0.05 0.032/0.001 0.014/0 0.016/0.001 0.024/0.001
0.15 0.013/0 0.032/0 0.024/0 0.028/0.003
0.25 0.017/0.001 0.025/0 0.04/0.006 0.071/0.051
0.35 0.035/0.006 0.045/0.023 0.139/0.162 0.447/0.745
Scenario 6 % early stop: 0.001
1. Description
2. Toxicity Parameter Estimation, True (α0, α1, α2) = (−1.46, 0.77, 1.39)
αˆ0 αˆ1 αˆ2
-1.427(0.379) 0.86(0.703) 1.164(0.71)
3. Efficacy Parameter Estimation,True (β0, β1, β2, β3, β4) = (0.3, 3.1, 1.55, ., .)
βˆ0 βˆ1 βˆ2 βˆ3 βˆ4
Linear 0.237(0.434) 3.226(1.123) 1.696(1.033) . .
Quadratic of agent A -0.02(0.683) 7.546(2.633) 1.894(1.172) -8.485(3.304) .
Quadratic of agent B 0.41(0.581) 3.936(1.426) 3.709(1.765) . -7.52(2.633)
Quadratic of both agents -0.294(0.827) 10.201(3.523) 5.628(2.276) -10.653(4.515) -8.081(3.232)
4. Model Selection percentages
Linear Quadratic of agent A Quadratic of agent B Quadratic of both agents
70.3% 13.3% 12.6% 3.7%
5. True Toxicity and Efficacy Probability: Tox/Eff
Dose Level (A\B) 0.1 0.4 0.7 1
0.1 0.06/0.08 0.1/0.14 0.16/0.23 0.25/0.35
0.4 0.08/0.23 0.13/0.35 0.21/0.5 0.31/0.65
0.7 0.11/0.5 0.17/0.65 0.26/0.77 0.38/0.86
1 0.14/0.77 0.22/0.86 0.32/0.92 0.45/0.95
6. Dose Allocation and Selection Percentages %pts/%sel
BODC=(1.384,0.05), BMS:%ins=32.2%
Dose inserted: 1.174(0.511), 0.256(0.25); Dose selected: 1.002(0.367), 0.341(0.316)
Dose Level(A\B) 0.1 0.4 0.7 1 Dose inserted Dose selected
0.1 0.031/0.003 0.002/0 0.009/0.002 0.015/0.012 0.079/0.202 0.287/
0.4 0.003/0.002 0.04/0.001 0.06/0.02 0.038/0.053
0.7 0.036/0.023 0.118/0.052 0.137/0.064 0.028/0.034
1 0.184/0.32 0.128/0.168 0.033/0.021 0.059/0.023
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Table 3: Time duration comparison between the adaptive cohort division algorithm
and the single cohort under the AAA. Entries are simulated trial duration is days for
two-agent trials of sample size 96 patients.
Scenario Algorithm Mean(Sd) Min∼Max p-value
Scenario 1 cohort divison 927.53(185.32) 346 ∼ 1076 < 0.0001∗∗
single cohort 1037.89(59.9) 558 ∼ 1077
Scenario 2 cohort divison 914.34(203.19) 367 ∼ 1075 < 0.0001∗∗
single cohort 1030.54(76.2) 495 ∼ 1074
Scenario 3 cohort divison 622.82(172.78) 26 ∼ 1062 < 0.0001∗∗
single cohort 1017.16(84.52) 26 ∼ 1071
Scenario 4 cohort divison 898.55(234.54) 6 ∼ 1067 < 0.0001∗∗
single cohort 944.86(249.64) 6 ∼ 1073
Scenario 5 cohort divison 1045.27(61.43) 522 ∼ 1081 0.2376
single cohort 1050.79(46.31) 599 ∼ 1077
Scenario 6 cohort divison 910.56(205.81) 28 ∼ 1073 < 0.0001∗∗
single cohort 1025.39(80.2) 28 ∼ 1072
Scenario 7 cohort divison 986.98(151.56) 357 ∼ 1076 < 0.0001∗∗
single cohort 1036.87(68.52) 522 ∼ 1077
Scenario 8 cohort divison 1011.31(127.67) 362 ∼ 1078 0.03∗
single cohort 1034.41(77.74) 523 ∼ 1079
Scenario 9 cohort divison 962.51(144.38) 350 ∼ 1079 < 0.0001∗∗
single cohort 1043.68(48.29) 534 ∼ 1076
Scenario 10 cohort divison 977.7(145.86) 23 ∼ 1075 < 0.0001∗∗
single cohort 1037.96(68.01) 23 ∼ 1077
